MediLink Dosed 1st Patient in Phase I Study with ADC YL202

MediLink Therapeutics today announced that the first patient has been successfully dosed with its Antibody Drug Conjugate (ADC) product YL202 in the United States and the first dose was well tolerated without any adverse events (AEs) observed. This is a multi-center nonrandomized, open-label, first-in-human phase I study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of YL202 in patients with locally advanced or metastatic epidermal growth factor receptor (EGFR)-mutated Non-small cell lung cancer (NSCLC) or hormone receptor (HR)-positive and HER2-negative breast cancer (BC). “The initiation of this study represents a significant milestone for MediLink Therapeutics, as it marks the second program of our ADC platform to enter the clinic in less than one year”, stated Tony Xue, PhD, Chairman, Founder & CEO.

2023-02-14Learn more

Jiangsu Public TV visit MediLink

2022-10-28Learn more

FDA Clearance of IND Application for YL202

September 3, 2022 - MediLink Therapetutics announced that YL202 has been cleared for its IND application by the U.S. Food and Drug Administration for Phase I first-in-human study

2022-09-03Learn more

1st patient dosed with product YL201 in the United States

2022-04-23Learn more

MediLink Therapeutics closes US$70 million Series B financing

SUZHOU, China, March 14, 2022 /PRNewswire/ -- MediLink Therapeutics (Suzhou) Co., Ltd (MediLink) recently announced completion of a US$70 million Series B financing. This round was led by LYFE Capital and Qiming Venture Partners, and co-invested by Legend Capital, Loyal Valley Capital and Highlight Capital (HLC), etc. The new funding will support clinical development of MediLink's new generation Antibody-Drug Conjugate (ADC) pipeline, as well as early discovery and development of novel conjugated drugs.

2022-04-14Learn more

FDA Clearance of IND Application for YL201

2022-04-12Learn more